weight loss medication tirzepatide Which Weight-Loss Drug Works the Best? How the weight loss drug

In a head-to-head open-label trial reported in February 2026, average weight loss at 84 weeks favored tirzepatide, and the sponsor noted CagriSema did not meet its prespecified non-inferiority target against tirzepatide

That matters because people do not just want to be thinner

PMID: 4 PopovJFarbodYChauhanUKalantarMHillLArmstrongDet al

Their primary outcomes were changes in body weight and BMI

As in prior years, the response rate for panel firms is higher than for non-panel firms

Oral GLP-1 formulations produce similar onset of appetite suppression, within one to four weeks, but achieve less total weight loss compared to injectable formulations